NIH #5P50CA247749-05
Developmental Research Program
Expiring Soon
- Amount
- $76K
- Period
- 2020-08-13 → 2026-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1R35CA305347-01
Overcoming Resistance to Targeted Therapy in Breast Cancer
Active
- Amount
- $1.1M
- Period
- 2025-08-20 → 2032-07-31
- PIs
- 1
- Est. capacity / PI
- ~15 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1R01CA296285-01A1
Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.
Active
- Amount
- $482K
- Period
- 2025-08-01 → 2030-07-31
- PIs
- 2
- Est. capacity / PI
- ~3 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5P50CA247749-04
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
- Amount
- $436K
- Period
- 2020-08-13 → 2025-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5P50CA247749-03
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
- Amount
- $423K
- Period
- 2020-08-13 → 2025-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5P50CA247749-02
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
- Amount
- $436K
- Period
- 2020-08-13 → 2025-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1P50CA247749-01
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
- Amount
- $350K
- Period
- 2020-08-13 → 2025-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA249666-04
HER2-mediated delivery of cytotoxic agents in solid tumors
- Amount
- $558K
- Period
- 2021-04-01 → 2025-03-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA249666-03
HER2-mediated delivery of cytotoxic agents in solid tumors
- Amount
- $576K
- Period
- 2021-04-01 → 2025-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA249666-02
HER2-mediated delivery of cytotoxic agents in solid tumors
- Amount
- $576K
- Period
- 2021-04-01 → 2025-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1R01CA249666-01A1
HER2-mediated delivery of cytotoxic agents in solid tumors
- Amount
- $588K
- Period
- 2021-04-01 → 2025-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA245069-05
Defining the impact of mutant oncogene zygosity
- Amount
- $385K
- Period
- 2020-03-01 → 2025-02-28
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA245069-04
Defining the impact of mutant oncogene zygosity
- Amount
- $397K
- Period
- 2020-03-01 → 2025-02-28
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA245069-03
Defining the impact of mutant oncogene zygosity
- Amount
- $397K
- Period
- 2020-03-01 → 2025-02-28
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA245069-02
Defining the impact of mutant oncogene zygosity
- Amount
- $405K
- Period
- 2020-03-01 → 2025-02-28
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1R01CA245069-01
Defining the impact of mutant oncogene zygosity
- Amount
- $405K
- Period
- 2020-03-01 → 2025-02-28
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA234361-05
Defining mechanisms of resistance to hormonal therapy in breast cancer
- Amount
- $403K
- Period
- 2018-12-05 → 2024-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA234361-04
Defining mechanisms of resistance to hormonal therapy in breast cancer
- Amount
- $403K
- Period
- 2018-12-05 → 2023-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA234361-03
Defining mechanisms of resistance to hormonal therapy in breast cancer
- Amount
- $411K
- Period
- 2018-12-05 → 2023-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA234361-02
Defining mechanisms of resistance to hormonal therapy in breast cancer
- Amount
- $411K
- Period
- 2018-12-05 → 2023-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1R01CA234361-01
Defining mechanisms of resistance to hormonal therapy in breast cancer
- Amount
- $411K
- Period
- 2018-12-05 → 2023-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA204999-05
Therapeutic approaches to ER mutant breast cancer
- Amount
- $411K
- Period
- 2017-01-01 → 2022-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA204999-04
Therapeutic approaches to ER mutant breast cancer
- Amount
- $411K
- Period
- 2017-01-01 → 2021-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA204999-03
Therapeutic approaches to ER mutant breast cancer
- Amount
- $380K
- Period
- 2017-01-01 → 2021-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5R01CA204999-02
Therapeutic approaches to ER mutant breast cancer
- Amount
- $392K
- Period
- 2017-01-01 → 2021-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1R01CA204999-01A1
Therapeutic approaches to ER mutant breast cancer
- Amount
- $392K
- Period
- 2017-01-01 → 2021-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1R01CA244812-01
Implications and Vulnerabilities of APOBEC Mutagenesis in Breast Cancer
- Amount
- $722K
- Period
- 2020-02-15 → 2020-08-13
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5K08CA134833-05
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer
- Amount
- $145K
- Period
- 2009-09-21 → 2014-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5K08CA134833-04
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer
- Amount
- $145K
- Period
- 2009-09-21 → 2014-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5K08CA134833-03
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer
- Amount
- $145K
- Period
- 2009-09-21 → 2014-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #5K08CA134833-02
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer
- Amount
- $145K
- Period
- 2009-09-21 → 2014-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH
NIH #1K08CA134833-01A1
Biologic and therapeutic implications of Akt activation in Her2+ breast cancer
- Amount
- $145K
- Period
- 2009-09-21 → 2014-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH